Cardiac toxicity of EGFR – 3rd generation TKI in patients with metastatic non-small cell lung cancer. Case report and literature data update
Article Sidebar
Main Article Content
Abstract
Purpose: The incidence of bronchopulmonary cancer has increased significantly in recent decades, especially in developed countries, and today it is the leading cause of death in men and the 3rd in women. The toxicities of tyrosine kinase inhibitor therapy are varied, with cardiac toxicities at the top of the pyramid. Because of the occurrence of these toxicities, depending on their intensity, the dose must be reduced or even treatment stopped.
Patient and method: We present the case of a 72-year-old patient, diagnosed in 2019 with non-small bronchopulmonary neoplasm with histology of adenocarcinoma with EGFR mutation, stage IV.
Results: In the oncology committee, it is decided to start targeted therapy with tyrosine kinase inhibitors of the first generation, Erlotinib, with a partial response to the treatment in the imaging evaluations, continued treatment until November 2020 when the T790M resistance mutation is detected. According to the new NCCN guidelines, therapy with the third-generation EGFR-TKI, Osimertinib, is initiated. In September 2021, the patient developed a non-ischemic acute antero-septal myocardial infarction that was complicated by LV apical aneurysm and severe LV systolic dysfunction, associated with therapy with tyrosine kinase inhibitors. Osimertinib treatment is stopped and third-line treatment with Vinorelbine is initiated.
Conclusions: Investigation and permanent monitoring of patients, in treatment with 3rd generation tyrosine kinase inhibitors, who may develop cardiac toxicities, but also a good management of these toxicities, lead to both increased survival and improved status of performance.
Article Details
References
Soria JC, Ohe Y, Vansteenkiste J et al., FLAURA Investigators. Osimertinib in untreated EGFT-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378:113-125
Patz Jr EF, Greco E, Gatsonis C et al. Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre diagnostic screening trial. Lancet Oncol 2016; 17:590-599
Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 2017;376:629–40.
Rosell R, Carcereny E, Gervais R, et al; Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small cell lung cancer (EURTAC): a multicentre, open-label, randomized phase 3 trial. Lancet Oncol. 2012, 13:239-246
Oyakawa T, Nakashima K, Naito T. Cardiac dysfunction caused by osimertinib. J Thorac Oncol 2017;10:e159–73.
Watanabe H, Ichihara E, Kano H, et al. Congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC). Intern Med 2017;56:2195–7.
Reale ML, Bianco M, Tabbo F, et al. Osimertinib-induced cardiac dysfunction in EGFR-mutated lung cancer: a case series of five patients. Am J Cancer Case Reports 2018;6:52–60.
Anad K, Ensor J, Trachtenberg B, et al. Osimertinib induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS). JACC Cardiooncology 2019;1:172–9.